Ultime notizie per Arqit Quantum (NASDAQ:ARQQ) Azioni

Arqit Quantum

Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology which makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. Arqit delivers its symmetric key agreement technology via its QuantumCloud. Its product, QuantumCloud, enables any device to download a lightweight software agent, which can create keys in partnership with any other device. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. Key revenue comes from the UK.

Arqit Quantum Inc

Earnings

News

Comerica Q3 2024 Adj. EPS $1.37 Beats $1.16 Estimate, Sales $811.000M Miss $811.617M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) with a Buy and maintains $9 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Edward White maintains Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) with a Buy and raises the price target from $21 to $22.

AURA

HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $22

The collaboration supports the licensing of part of Curiosity Stream&#39;s content portfolio in China, Hong Kong, and Macau, bringing 56 unique titles, amounting to 148 hours of premium factual content, to audiences across these territories through various platforms. The deal encompasses a diverse range of programming, from short-form documentary series to premium long-form content.

CURI

Curiosity Inks Strategic Distribution Partnership With Off The Fence; Deal Broadens Company's Footprint Across China, Hong Kong, And Macau

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Arqit Quantum (ARQQ) has released an update. Arqit Quantum Inc. announces its Annual General Meeting for shareholders, scheduled for September 18, ...

Arqit Quantum Schedules Crucial Shareholder Meeting

Warning: ARQQ is at high risk of performing badly

Arqit Quantum to regain minimum bid price compliance through reverse share split

Arqit Quantum (ARQQ) has released an update. Arqit Quantum Inc. has announced a 25:1 reverse share split to regain compliance with Nasdaq's minimum...

Arqit Quantum Executes Reverse Share Split

Arqit Quantum CEO steps down

Arqit Quantum (ARQQ) has released an update. Arqit Quantum Inc. has announced a major leadership change with Andy Leaver, a veteran in the software...

Arqit Quantum Inc. Appoints New CEO for Growth Era

Arqit Quantum shares fall on $13.6M direct offering

Arqit Quantum (ARQQ) has released an update. Arqit Quantum Inc. has issued purchase warrants for ordinary shares exercisable at $2.50 each, followi...

Arqit Quantum Offers Streamlined Share Warrants

How To Make Money In Quantum

Arqit Quantum (ARQQ) has released an update. Arqit Quantum Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, m...

Arqit Quantum Regains Nasdaq Compliance

ARQQ

IONQ

Press Releases

Sparkle Successfully Completes First Test of an International VPN Protected with Quantum Encryption

Arqit Quantum Inc. Announces Financial and Operational Results for the First Half of Fiscal Year 2024

Arqit Launches Encryption Intelligence Service

Small Cap

Opinion

Quantum Computing Pioneers Making Strides in Cybersecurity

Gateway Group Announces Preliminary Sponsors and Additional Presenting Companies for September Gateway Conference

Sparkle Pioneers Network-as-a-Service (NaaS) with Quantum-Safe Internet Use Case

Arqit Quantum Inc. Announces 25:1 Reverse Share Split

Arqit announces leadership transition with the appointment of a new Chief Executive Officer

Financing

Arqit Quantum Inc. Announces $13.6 Million Registered Direct Offering

ACNT

AERT

AEYE

AIRG

AMPX

AMRK

ARQQW

ASPN

ATEX

BBSI

BKSY

BNZI

BREZ

BTBT

BYRN

CORZ

CPSS

CSE:SCPE

DEFTF

DUOT

ELVA

FTHM

GAIA

GCTS

GENK

HEAR

HTCR

JTAI

LINK

LTRX

MAPPF

MIGI

MSFT

MYPS

NATR

NVDA

OOMA

PHUN

PRLB

PXDT

QBTS

QTRHF

QUISF

SCPCF

SNCR

SNPO

SOWG

SSTI

TRUE

TSX:KITS

TSX:QTRH

TSX:QUIS

TYGO

VTSI

WKHS

ZCAR

HC Wainwright & Co.

Deutsche Bank

Comments

Arqit Quantum

Notizie

Ultime notizie per Arqit Quantum (NASDAQ:ARQQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO